SCHEMBL6702971

SCHEMBL6702971

COC(OC)Oc1cccc(-c2ccc3cn[nH]c3c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 11/20 0.66
FGFR2 P21802 5/20 0.66
FGFR3 P22607 2/20 0.66
CLK2 P49760 3/20 0.46
CLK4 Q9HAZ1 3/20 0.46
MAP4K4 O95819 3/20 0.46
AURKB Q96GD4 3/20 0.46
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
CDK8 P49336 2/20 0.46
PRKX P51817 2/20 0.46
PRKD3 O94806 2/20 0.46
NTRK1 P04629 2/20 0.46
CSNK1A1 P48729 2/20 0.46
NTRK3 Q16288 2/20 0.46
NTRK2 Q16620 2/20 0.46
TAOK1 Q7L7X3 2/20 0.46
PRKACA P17612 1/20 0.46
LTK P29376 1/20 0.46
TGFBR1 P36897 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6702968 0.77 FGFR1 (0.71) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL28104327 0.75 FGFR1 (0.65) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL8264120 0.75 FGFR1 (0.70) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL2460902 0.74 FGFR1 (1.00) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL8266373 0.72 FGFR1 (0.70) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL16711157 0.70 MAPT (0.49) FGFR1FGFR2FGFR3DYRK1AROCK2
SCHEMBL13115655 0.70 FGFR1 (0.71) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL16935421 0.69 FGFR1 (1.00) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL10269367 0.69 FGFR1 (0.55) FGFR1FGFR2FGFR3CLK2CLK4
SCHEMBL2461196 0.68 FGFR1 (0.64) FGFR1FGFR2FGFR3CLK2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220248-A1 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE KANIA ROBERT STEVEN (US) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220248-A1 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE CDK3, BRAF, ROCK1 FGFR1 262/4885FGFR2 583/4885FGFR3 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.